May, 2023, Eutropics has entered an exploratory research agreement with Massachusetts General Brigham, a teaching hospital of Harvard Medical School, to support application of the PRIMABS™-Dx platform in tumors associated with Neurofibromatosis Type 1 (NF1). As part of this collaboration, Eutropics and the laboratory of Dr. James A. Walker, Assistant Professor of Neurology, will generate CRISPR‑engineered apoptotic signaling modified cell lines to model resistance mechanisms in NF1‑associated tumors, including those treated with currently used drugs. These tools will enable functional profiling of apoptotic signaling and anti-apoptotic BCL‑2 family proteins, with the goal of better defining how and when to target resistance factors in NF1‑driven solid tumors.
